Innovative Discovery Center (IDC)

IDC is establishing an ecosystem based on diverse R&D research outcomes, collaborating with Singapore’s R&D center. This ecosystem covers the entire process from preclinical stages, clinical trials, marketing approval to sales. IDC focuses primarily on antibody-centric new drug research (including monoclonal antibodies, bispecific antibodies and fusion antibodies), diagnostics, and vaccines and more. Moreover, IDC is actively fostering open collaboration in the development of novel modalities of biopharmaceuticals.

Pipeline : PBP1510

Being a first-in-class anti-PAUF treatment, PBP1510 prevents the progression and metastasis of the cancer induced by PAUF (Pancreatic Adenocarcinoma Up-regulated Factor) and creating a more responsive environment for antitumor immunotherapy. Thus, it is expected to provide significant benefit to patients suffering from PAUF-positive pancreatic cancer.

In 2020, PBP1510 was granted Orphan Drug Designation by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and Korea Ministry of Food and Drug Safety (MFDS). Currently, it is undergoing phase 1/2a clinical trial in Europe and U.S.

Prestige Biopharma Group

Innovative Discovery Center (IDC)

Meet our CMCB team at Prestige Biopharma

Innovative Discovery Center (IDC)